Abbott Laboratories (ABT) Q2 2024 Earnings Results

Abbott Labs Beats on EPS, Stock Down 4.4%

Abbott Labs reported a slight earnings beat, which indicates some strength in their operations. However, the stock fell 4.4% in reaction, likely due to the lack of revenue data and guidance. Investors may be concerned about future growth prospects given the current market environment.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.14	N/A	+3.54%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding future performance. They emphasized their commitment to innovation and adapting to market conditions.

Management highlighted the resilience of their product portfolio despite market challenges.

They acknowledged ongoing pressures but expressed confidence in long-term growth strategies.

Abbott Labs Beats on EPS, Stock Down 4.4%

Key numbers

Management commentary

Abbott Laboratories

More earnings this week

Abbott Labs Beats on EPS, Stock Down 4.4%

Key numbers

Management commentary